Once-Weekly Semaglutide in Adults With Alcohol Use Disorder JAMA Psychiatry This randomized clinical trial explored if glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide reduces alcohol consumption and craving in adults with alcohol use disorder (AUD). Relative to placebo, low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration procedure. Over the course of nine weeks of treatment, semaglutide led to reductions in some but not all measures of weekly consumption, significantly reduced weekly alcohol craving relative to placebo, and led to greater relative reductions in cigarettes per day in a subgroup of participants with current cigarette use. These results justify larger clinical trials of incretin therapies for AUD. Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related